NewAmsterdam Pharma Company NV
NAMS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.67B
Close$
$2.94
89.4% downside
Current Fair Value
89.4% downsideOvervalued by 89.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.67 Billion |
|---|---|
| Enterprise Value | $3.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.11 |
| Outstanding Shares | 123,370,232 |
Return
| Return on Equity | -41.10% |
|---|---|
| Return on Assets | -36.84% |
| Return on Invested Capital | -40.57% |
Valuation & Multiples
| P/E Ratio | -12.78 |
|---|---|
| PEG | -4.75 |
| Price to Sales | - |
| Price to Book Ratio | 5.53 |
| Enterprise Value to Revenue | 456.82 |
| Enterprise Value to EBIT | -12.7 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$2.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$7.54 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 6.9406▲ 509.80% |
|---|---|
| Total Calls | 306,300▲ 4.61% |
| Total Puts | 2,125,900▲ 294.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 102.56%▼ 5.49% |
|---|---|
| Total Invested | $4.20B▲ 5.97% |
| Investors Holding | 213▲ 32.00% |
ESG Score
No data